Drug delivery’s next bottleneck isn’t innovation, it’s industrial capacity - Pharmaceutical Technology

Drug delivery’s next bottleneck is manufacturing capacity: scale, validation, and resilient supply chains. Surging demand for injectable therapies (led by GLP‑1s) is exposing a new constraint in drug delivery: not innovation, but the ability to industrialise and manufacture devices at scale. As demand for injectable therapies accelerates, manufacturing capacity (not device innovation) is emerging as the key constraint on delivering treatments at scale. Credit: Quvara New biologics, expanding indications, and rapid growth in GLP-1 therapies are bringing effective treatments to unprecedented numbers of patients. Yet this progress is exposing a constraint – manufacturing capacity . The next major bottleneck may…

Source: Pharmaceutical Technology